Novo Nordisk Inc.
Lobbying client
The U.S. subsidiary of Novo Nordisk, the Danish pharmaceutical company known for insulin products and GLP-1 drugs including Ozempic and Wegovy. It filed 12 lobbying disclosures since 2024, reaching all 51 council members through Patrick B. Jenkins & Associates, on potential regulation of dietary aids and efforts to improve the health of the city workforce.
- Council members lobbied
- 51 (citywide)
- Filings (since 2024)
- 12
- Lobbying compensation (since 2024)
- $276,000
Represented by lobbyist firms
- Patrick B. Jenkins & Associates Lobbyist firm
What they lobbied on
subjects from their filings
- Rule - Potential regulation regarding dietary aids
- Rule - Seeking to improve health of city workforce